FDA Approves Merck's Belzutifan With Lenvatinib For Advanced Kidney Cancer With Clear Cell Component

The FDA has approved Merck's drug Belzutifan in combination with Lenvatinib for the treatment of advanced renal cell carcinoma with a clear cell component. This approval is expected to enhance Merck's portfolio in oncology and potentially impact its revenue positively. The stock ticker for Merck is MRK.